icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Safety and Efficacy of 12 Weeks of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-Infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials
 
 
  Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
 
Steven L. Flamm1; Cheng-Yuan Peng2; Oren Shibolet3; Ronald Nahass4; Peggy Hwang5; Eliav Barr5; Michael Robertson5; Barbara Haber5 1Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2China Medical University Hospital, Taichung City, Taiwan; 3Tel-Aviv Medical Center,Tel-Aviv, Israel; 4ID Care, Hillsborough, NJ, USA; 5Merck & Co., Inc., Kenilworth, NJ, USA

1023171

1023172

1023173

1023174

1023175

1023176

1023177

1023178